The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials. Additional links to TB R&D news are included.
The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Included are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug development and research.
The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB. Additional links to TB R&D News are included.
Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year. We present links and summaries of events, publications, messages, and news coverage leading up to World TB Day.
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years. This is part two of our interview with him.
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.
In this week’s TB R&D update, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. The article is published online ahead of print this month in Thorax and is entitled “The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.” Also, links to additional news in TB R&D are included.
An interview with Dr. Anneke Hesseling, the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa.